Form 4: Vaccinex CEO Maurice Zauderer Reports Acquisition of Shares and Warrants
SEC Filing (Form 4)
Vaccinex CEO Maurice Zauderer reports the acquisition of common stock and warrants, along with adjustments to existing holdings, as detailed in a recent SEC filing.
Summary
- Maurice Zauderer, CEO of Vaccinex, Inc., filed a Form 4 with the SEC detailing changes in beneficial ownership.
- On March 28, 2024, Zauderer acquired 38,610 shares of common stock at a price of $7.77 per share.
- He also acquired warrants to purchase 38,610 shares of common stock at an exercise price of $7.64, expiring on March 28, 2029.
- The filing also reflects indirect ownership through various entities, including the Jeremy C. Zauderer Trust, the Jordan M. Zauderer Trust, and Vaccinex (Rochester), L.L.C.
- Zauderer disclaims beneficial ownership of shares held by these trusts and Vaccinex (Rochester), L.L.C., except to the extent of his pecuniary interest.
- The filing details various stock options held by Zauderer with different exercise prices and vesting schedules.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing primarily reports transactions without expressing an opinion on the company's prospects. The CEO's purchase could be seen as slightly positive, but it's not definitive.
Positives
- The CEO's acquisition of shares and warrants could be interpreted as a positive signal, indicating confidence in the company's future prospects.
Risks
- The filing itself doesn't inherently indicate risks, but investors should consider the context of these transactions in relation to the company's overall financial health and strategic direction.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The information is useful to investors to understand management's alignment with company goals.
Comparison to Industry Standards
- Comparing insider transactions to those of peers like BioNTech, Moderna, or Novavax can provide context.
- However, direct comparisons are difficult without understanding the specific circumstances of each transaction and the overall financial health of the companies.
Stakeholder Impact
- The reported transactions may influence investor sentiment and potentially impact the stock price.
Key Dates
| Date | Description |
|---|---|
| 02/08/2024 | Warrant (Right to Buy) $ 14 |
| 03/20/2024 | Stock Option (Right to Buy) $ 9.15 (7) |
| 03/28/2024 | Transaction date for acquisition of common stock and warrants. |
| 03/31/2024 | Stock Option (Right to Buy) $ 3,129 (3) |
| 04/01/2024 | Date of signature for the report. |
| 06/30/2024 | Stock Option (Right to Buy) $ 3,129 (3) |
| 12/23/2025 | Stock Option (Right to Buy) $ 1,491 (3) |
| 03/30/2028 | Stock Option (Right to Buy) $ 92.26 (6) |
| 03/20/2029 | Stock Option (Right to Buy) $ 9.15 (7) |
| 04/02/2031 | Stock Option (Right to Buy) $ 615.3 (4) |
| 04/01/2032 | Stock Option (Right to Buy) $ 270.9 (5) |
Keywords
Vaccinex, Zauderer, SEC Form 4, Beneficial Ownership, Stock, Warrants, Options
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.